Skip to main content

Table 1 Comparison of demographic and clinical characteristics of included and excluded CRC patients

From: Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry

 

Included patients (n = 433)

Excluded patients

(n = 70)

p-value*

Mean age in years (SD)

66.3 (9.5)

69.4 (9.9)

0.01

Male

61.2%

68.6%

0.24

Mean BMI (SD)*

26.3 (5.2)

26.0 (3.8)

0.55

Comorbidities at time of enrollment into registry

 Hypertension

41.3%

45.7%

0.81

 Diabetes mellitus with end-organ damage

0.7%

2.9%

0.27

 Diabetes mellitus without end-organ damage

14.6%

18.6%

0.50

 Thyroid disease

9.0%

4.3%

0.35

 Coronary heart disease

8.3%

8.6%

1.00

 Tumor other than colorectal or lymphoma or leukemia

7.9%

7.1%

1.00

 Chronic gastric or bowel disease

6.7%

1.4%

0.18

 Adiposity

6.5%

2.9%

0.44

 Chronic pulmonary disease

5.8%

4.3%

0.90

 Anemia

4.4%

4.3%

1.00

 Heart failure

4.2%

7.1%

0.44

 Kidney disease

3.5%

8.5%

0.15

 Urogenital disease

3.2%

5.7%

0.07

 Cerebrovascular disease

2.5%

1.4%

1.00

 Myocardial infarction

2.5%

0.0%

0.47

 Peripheral artery occlusive disease

2.1%

1.4%

1.00

 Mild liver disease

1.4%

0.0%

1.00

 Moderate or severe liver disease

0.7%

0.0%

1.00

 Polyneuropathy

1.9%

1.4%

1.00

 Peptic ulcer disease

0.5%

0.0%

1.00

 Connective tissue disease

0.5%

0.0%

1.00

 Metastatic solid tumor other than colorectal

0.5%

0.0%

1.00

 Hemiplegia

0.2%

0.0%

1.00

 AIDS

0.2%

0.0%

1.00

 Myocardial insufficiency

0.0%

0.0%

1.00

 Dementia

0.0%

1.4%

0.16

Localization of primary tumor

  

0.82

 Colon

56.4%

58.6%

 Rectum

43.4%

41.4%

Inoperable primary tumor

19.9%

24.3%

0.63

Tumor stage (UICC) at primary diagnosis

  

0.82

 I

3.7%

4.3%

 II

7.2%

5.7%

 III

13.9%

11.4%

 IV

66.5%

72.9%

Progression prior to questioning

  

0.27

 0

75.3%

75.7%

 1

16.6%

12.9%

 2 or more

4.4%

7.1%

Metastases

   

 Liver

61.4%

58.6%

0.79

 Lung

23.8%

21.4%

0.83

 Peritoneal

14.6%

20.0%

0.49

 Bone

3.0%

2.9%

0.93

Number of metastatic localizations prior to questioning

  

< 0.01

 0

10.9%

7.1%

 1

51.2%

55.7%

 2

24.9%

27.1%

 3 or more

7.6%

5.7%

Treatment line at time of questioning

  

0.93

 First-line palliative

55.2%

60.0%

 Break after first-line

23.3%

20.0%

 Second-line palliative or break after second-line

15.5%

14.3%

 Third-line palliative or later

5.1%

5.7%

Most current chemotherapy at time of questioning

  

< 0.01

 Irinotecan-based

44.8%

44.3%

 Oxaliplatin-based

37.4%

34.3%

 Fluoropyrimidine monotherapy

10.4%

15.7%

 Irinotecan plus oxaliplatin

4.9%

2.9%

Additional antibody treatment

  

0.68

 None

22.6%

28.6%

 VEGF

49.7%

42.9%

 EGFR

26.1%

27.1%

RAS mutation status

  

0.74

 Wild-type

38.1%

42.9%

 Mutation

40.9%

40.0%

  1. *Independent t-test was applied for continuous variables. Chi2-test or Fisher’s exact test was applied for categorical variables
  2. Statistically significant at alpha = 0.05
  3. Percentages may not add up to 100% due to patients with missing data